Nebulizer use in tobacco-exposed SPIROMICS participants with or at risk of COPD

J. Fazio (Los Angeles, United States), A. Hong (Los Angeles, United States), D. Markovic (Los Angeles, United States), R. Barr (New York, United States), E. Bleecker (Tucson, United States), R. Bowler (Denver, United States), D. Couper (Chapel Hill, United States), J. Curtis (Ann Arbor, United States), B. Drummond (Chapel Hill, United States), S. Fortis (Iowa City, United States), M. Han (Ann Arbor, United States), L. Holland (Chapel Hill, United States), V. Kim (Philadelphia, United States), F. Martinez (New York, United States), J. Ohar (Winston-Salem, United States), V. Ortega (Phoenix, United States), R. Paine (Salt Lake City, United States), M. Wells (Birmingham, United States), P. Woodruff (San Francisco, United States), R. Buhr (Los Angeles, United States), C. Cooper (Los Angeles, United States), D. Tashkin (Los Angeles, United States), I. Barjaktarevic (Los Angeles, United States)

Source: International Congress 2022 – COPD management: comorbidities, cohorts and real-world studies

Session: COPD management: comorbidities, cohorts and real-world studies
Session type: Thematic Poster
Number: 2121

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Fazio (Los Angeles, United States), A. Hong (Los Angeles, United States), D. Markovic (Los Angeles, United States), R. Barr (New York, United States), E. Bleecker (Tucson, United States), R. Bowler (Denver, United States), D. Couper (Chapel Hill, United States), J. Curtis (Ann Arbor, United States), B. Drummond (Chapel Hill, United States), S. Fortis (Iowa City, United States), M. Han (Ann Arbor, United States), L. Holland (Chapel Hill, United States), V. Kim (Philadelphia, United States), F. Martinez (New York, United States), J. Ohar (Winston-Salem, United States), V. Ortega (Phoenix, United States), R. Paine (Salt Lake City, United States), M. Wells (Birmingham, United States), P. Woodruff (San Francisco, United States), R. Buhr (Los Angeles, United States), C. Cooper (Los Angeles, United States), D. Tashkin (Los Angeles, United States), I. Barjaktarevic (Los Angeles, United States). Nebulizer use in tobacco-exposed SPIROMICS participants with or at risk of COPD. 2121

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.